Mar 08, 2023 / 03:30PM GMT
Max Masucci - TD Cowen, Research Division - MD & Senior Research Analyst
Thanks everybody for being here on day 3 TD Cowen's 43rd Annual Confrence. I'm pleased to be joined by Guardant Health with CEO, Helmy Eltoukhy and CFO, Mike Bell, who probably do not need an in-depth introduction. But maybe just to kick off, you did just report results. What do you consider the headline takeaways from '22?
Helmy Eltoukhy - Guardant Health, Inc. - Co-Founder, Co-CEO & Chairman
Yes. So we had, I think, an excellent year, 42% growth in terms of clinical volume. I think overall 20% growth in terms of revenue and then obviously, making tangible progress in terms of these new emerging areas of MRD and obviously, a successful readout of Eclipse. And so I think '22 was a pivotal year with a 10-year anniversary from founding the company, and they had really brought to kind of tangible reality. There's a vision of really transforming the entire continuum of cancer care from beginning to end. And so now we have, I think, 3 franchises that are truly disruptive and have
Guardant Health Inc at Cowen Health Care Conference Transcript
Mar 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers